How Does This Insulin Device Business Operate?
Insulet Corp is a medical device company focused on insulin delivery for people with diabetes. Its core business centers on a wearable, tubeless insulin pump system and the supporting ecosystem around it. The company sells its products in the U.S. and internationally, serving patients through the healthcare channel. With an equity value around USD 11.4 billion, it sits at a scale where execution and continuity matter.
Can Profitability Hold as Growth Accelerates?
FundamentalsIn its latest annual results (reported in USD), Insulet produced USD 716.1 million of cash alongside only USD 36.8 million of total debt, keeping the balance sheet lightly encumbered. That financial posture sits next to a year where revenue reached about USD 2.7 billion, with EBIT of roughly USD 474 million and net income of about USD 247 million.
Growth remained brisk, with revenue up 30.7% year over year, while profitability held at a 14.57% operating margin and a 10.44% net profit margin on a TTM basis. Capital intensity showed up in spending: USD 191.6 million of capex exceeded USD 90.4 million of depreciation and amortization, and the cash flow proxy came in at about USD 280 million after that investment.
Is the Market Paying Up for Growth?
DCF / MultiplesWith the stock at USD 164.43, the DCF range runs from USD 79.88 in a weaker scenario through USD 150.08 at the central case to USD 248.45 in a stronger outcome. At this price, the shares sit above the central estimate while still inside the overall valuation band.
Headline pricing also reflects a growth-tilted setup, with a 38.12 P/E (TTM) and 26.75 EV/EBITDA (TTM) alongside a 3.98 price-to-sales (TTM).
Valuation Leaves Little Cushion
TakeawayThe balance sheet looks built for durability, with low debt. The case leans on keeping growth strong while funding capex. If spending rises faster than cash generation, resilience weakens. At today’s price, the valuation gives less room for stumbles.